Expert video report on Diffuse Large B-Cell Lymphoma

ICML-15

Speaker: Anastasios Stathis

Anastasios Stathis reports from ICML-15 in Lugano from 2 important studies from the plenary session challenging the current standard of care, R-CHOP chemo-immunotherapy in diffuse large B-cell lymphoma.

  • Abstract 05: ROBUST: FIRST REPORT OF PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/RCHOP (R2-CHOP) VS PLACEBO/R-CHOP IN PREVIOUSLY UNTREATED ABC-TYPE DIFFUSE LARGE B-CELL LYMPHOMA U. Vitolo, Turin (Italy)
  • Abstract 06: ADDITION OF LENALIDOMIDE TO R-CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG-ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R-CHOP G.S. Nowakowski, Rochester, MN (USA)